CCR5 and lymphoma: This supports the simultaneous targeting of both lymphoma cells and Mφ with PI3K inhibitors, and the use of Maraviroc for the blocking of CCR5 in these cells (Casagrande et al., 2019; Locatelli et al., 2018).